Диссертация (1090326), страница 36
Текст из файла (страница 36)
T.1. C. 124125 (стендовый доклад).38. IvanovI. Molecular enzymology ofeicosanoid synthesizing enzymes: newperspectives in lipoxygenase research // CUT International Prestigious Research197Meeting, Central University of Technology. Bloemfontein, Republic of South Africa(RSA), 11th October 2006 (устный доклад).39. Ivanov I., Saam J., Walther M., Holzhütter H.G., Kühn H. Targeted oxygen movementin 12/15-Lipoxygenases.
MD-simulations and the site directed mutagenesis // AnnualEICOSANOXMeeting.Aigen/Ennstal,Austria,September5–82007.www.eicosanox.org/events/program_2007.pdf (устный доклад).40. Ivanov I., Walther M., Wiesner R., Myagkova G., Kuhn H. The role of N-terminaldomain for functionality of mammalian 12/15-LOX // Proceedings of the 10thInternational Conference Bioactive Lipids in Cancer, Inflammation and RelatedDiseases. Montreal, Canada, September 16 –19 2007. P. 165 (стендовый доклад).41. Ivanov I., Walther M., Wiesner R., Myagkova G., Kuhn H.
Technology of investigationof the interaction between N-terminal and catalytic C-terminal domains to determineprotein stability and biological function of 12/15-lipoxygenases // Тезисы докладов XIIМеждународнойнаучно-техническойконференцииНаукоемкиехимическиетехнологии. Волгоград, 9–11 сетября 2008. С. 146-147 (стендовый доклад).42. Ivanov I. Structural flexibility of 12/15-lipoxygenases // Annual EICOSANOX Meeting.KarolinskaInstitutet,Stockholm,Sweden;December3–5www.eicosanox.org/events/eicosanox%20program%202009_final_1201.pdf2009.(устныйдоклад).43. Ivanov I., Shang W., Masgrau L., Svergun D. I., Skrzypczak-Jankun E., González-Lafont À., Kühn H.
A role of allosteric effector 13(S)-H(p)ODE in ligand inducedformation of transient dimers of mammalian 12/15-LOX: new aspects of lipoxygenasecatalysis // Book of abstracts of XVII Lipid Meeting. Leipzig, Germany, November 3–42011. P. 80 (стендовый доклад).44.
Ivanov I., Di Venere A., Masgrau L., Mei G., Kühn H. On structural flexibility of rabbitALOX15: interdomain movement, oligomerisation and catalytic activity // Proceedingsof the 14th International Conference on Bioactive Lipids in Cancer, Inflammation andRelated Diseases. Budapest, Hungary, July 12–15, 2015. P. 187 (стендовый доклад).198СПИСОК ЦИТИРУЕМОЙ ЛИТЕРАТУРЫ:1.Brash A.R. Lipoxygenases: Occurrence, functions, catalysis, and acquisition ofsubstrate // J.
Biol. Chem. 1999. V. 274. P. 23679–23682.2.Ivanov I., Heydeck D., Hofheinz K., Roffeis J., O'Donnell V.B., Kuhn H., WaltherM. Molecular enzymology of lipoxygenases // Arch. Biochem. Biophys. 2010. V.503, P. 161–174.3.HaeggstromJ.Z.,C.D.FunkLipoxygenaseandleukotrienepathways:biochemistry, biology, and roles in disease // Chem.
Rev. 2011. V. 111. P. 5866–5898.4.Kuhn, H., Banthiya, S., van Leyen K. Mammalian lipoxygenases and theirbiological relevance // Biochim. Biophys. Acta. 2015. V.1851. P. 308–330.5.Pace-Asciak C.R. The hepoxilins and some analogues: a review of their biology //Br. J. Pharmacol. 2009. V.158. P. 972–981.6.Sachs-Olsen C., Sanak M., Lang A.M., Gielicz A., Mowinckel P., Lodrup CarlsenK.C., Carlsen K.H., Szczeklik, A.
Eoxins: a new inflammatory pathway inchildhood asthma // J. Allergy. Clin. Immunol. 2010. V.126, P. 859–867. e9.7.Romano M. Lipoxin and aspirin-triggered lipoxins // Scientific World Journal.2010. V. 10. P. 1048–1064.8.Serhan C.N., Petasis N.A. Resolvins and protectins in inflammation resolution //Chem.
Rev. 2011. V. 111. P. 5922–5943.9Yoo S., Lim J.Y., Hwang S.W. Resolvins: Endogenously-generated potentpainkillingsubstancesandtheirtherapeuticNeuropharmacol. 2013. V. 11. P. 664–676.199perspectives//Curr.10.Savari S., Vinnakota K., Zhang Y., Sjolander A. Cysteinyl leukotrienes and theirreceptors: bridging inflammation and colorectal cancer // World J. Gastroenterol.2014. V. 20, P. 968–977.11.Funk C.D., Chen, X.S., Johnson, E.N., Zhao, L. Lipoxygenase genes and theirtargeted disruption // Prostaglandins Other Lipid Mediat. 2002. V. 68-69.
P. 303–312.12.Duroudier N.P., Tulah A.S., Sayers I. Leukotriene pathway genetics andpharmacogenetics in allergy // Allergy. 2009. V. 64. P. 823–839.13Hersberger M. Potential role of the lipoxygenase derived lipid mediators inatherosclerosis: Leukotrienes, lipoxins and resolvins.
// Clin. Chem. Lab. Med.2010. V. 12. P. 1063–1073.14.Chawengsub Y., Gauthier K.M., Campbell W.B. Role of arachidonic acidlipoxygenase metabolites in the regulation of vascular tone // Am. J. Physiol.Heart Circ. Physiol. 2009. V. 297. P. 495–507.15.Mochizuki N., Kwon Y.G. 15-Lipoxygenase-1 in the vasculature: Expanding rolesin angiogenesis // Circ. Res.
2008. V. 102. P. 143–145.16.Bhattacharya S., Mathew G., Jayne D.G., Pelengaris S., Khan M. 15Lipoxygenase-1 in colorectal cancer: a review // Tumour Biol. 2009. V. 30. P.185–199.17.Pidgeon G.P., Lysaght J., Krishnamoorthy S., Reynolds J.V., O’Byrne K., Nie D.,Honn K.V. Lipoxygenase metabolism: Roles in tumor progression and survival //Cancer Metastasis Rev. 2007.
V. 26. P. 503–524.18.Cimen I., Tuncay S., Banerjee S. 15-Lipoxygenase-1 expression suppresses theinvasive properties of colorectal carcinoma cell lines HCT-116 and HT-29 //Cancer Sci. 2009. V. 100, P. 2283–2291.19.Cimen I., Astarci E., Banerjee S. 15-lipoxygenase-1 exerts its tumor suppressiverole by inhibiting nuclear factor-kappa B via activation of PPAR gamma // J. CellBiochem. 2011. V. 112. P. 2490–2501.20020.Nunemaker C.S., Chen M., Pei H., Kimble S.D., Keller S.R., Carter J.D., Yang Z.,Smith K.M., Wu R., Bevard M.H., Garmey J.C., Nadler J.L.
12-Lipoxygenaseknockout mice are resistant to inflammatory effects of obesity induced by Westerndiet // Am. J. Physiol. Endocrinol. Metab. 2008. V. 295. P. E1065–E1075.21.Lieb D.C., Brotman J.J., Hatcher M.A. Aye M.S. Cole B.K., Haynes B.A.,Wohlgemuth S.D., Fontana M.A., Beydoun H., Nadler J.L., Dobrian A.D. Adiposetissue 12/15 lipoxygenase pathway in human obesity and diabetes // J. Clin.Endocrinol. Metab. 2014. V. 99, P. E1713–E1720.22.Steinhilber D., Hofmann B. Recent advances in thesearch of novel 5lipoxygenase inhibitors // Basic Clin. Pharmacol.Toxicol. 2012. V.114. P.
70–77.23.Dunn C.J., Goa K.L. Zafirlukast. An update of its Pharmacology nd therapeuticefficacy in asthma // Drugs 2001. V.61. P. 285–31523.24.Theron A.J., Steel H.C., Trintinger G.R., Gravett C.M., Andrson R., Feldman C.Cystienyl leukotriene receptor-1 antagonists as modulators of innate cell function// J. Immunol. Res. 2014.
Article ID: 608930.25.Sadeghian H, Jabbari A. 15-Lipoxygenase inhibitors: a patent review // ExpertOpin. Ther. Pat. 2015. DOI:10.1517/13543776.2016.11113259.26.Wecksler A.T., Kenyon V., Deschamps J.D., Holman T.R. Substrate specificitychanges for human reticulocyte and epithelial 15-lipoxygenases reveal allostericproduct regulation // Biochemistry 2008. V.47. P. 7364–7375.27.Wecksler A.T., Jacquot C., van der Donk W.A., Holman TR. Mechanisticinvestigations of human reticulocyte 15- and platelet 12-lipoxygenases witharachidonic acid // Biochemistry 2009. V.
48. P. 6259–6267.28.Shappell S.B., Manning S., Boeglin W.E., Guan Y.F., Roberts R.L., Davis L.,Olson S.J., Jack G.S. Coffey C.S., Wheeler T.M., Breyer M.D., Brash, A. R.Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNAexpression in prostate carcinoma// Neoplasia 2001. V. 3, P. 287–303.20129.Butler R.M., Mitchell S.H., Tindall D.J., Young C.Y. Nonapoptotic cell deathassociated with S-phase arrest of prostate cancer cells via the peroxisomeproliferator-activated receptor γ ligand, 15-deoxy-δ12,14-prostaglandin J2 // CellGrowth Differ.
2000. V. 11. P. 49–61.30.Hsi L.C., Wilson L., Nixon J., Eling, T.E. 15-Lipoxygenase-1 metabolites downregulate peroxisome proliferator- activated receptor γ via the MAPK signalingpathway // J. Biol. Chem. 2001. V. 276. P. 34545–34552.31.Gillmor S.A., Villasenor A., Fletterick R., Sigal E., Browner M.F.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
